XML 18 R7.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities:      
Net loss $ (212,638) $ (679,171) $ (272,072)
Adjustments to reconcile net loss to net cash used in operating activities:      
Goodwill impairment 0 436,479  
Depreciation and amortization expense 32,973 31,512 26,167
Provisions for credit losses 7,090 1,057 806
Inventory write-off 1,893    
Amortization of deferred contract acquisition costs 2,457 2,261 1,684
Amortization of deferred contract fulfillment costs 459 432 620
Noncash compensation costs incurred by selling shareholders     11,139
Accretion of discounts on debt securities   (10,010)  
Interest on debt securities   10,010  
Stock-based compensation expense 47,542 72,246 67,675
Loss on equity method investment 3,110 2,590 2,278
Deferred income taxes (243) (242) (2,524)
Changes in operating assets and liabilities, net of acquisition:      
Accounts receivable (25,012) 3,248 (8,140)
Inventories 1,901 2,085 (1,207)
Deferred contract acquisition costs (3,287) (4,499) (2,771)
Prepaid expenses and other current assets 2,601 4,694 (161)
Other assets (217) (76) (235)
Accounts payable 159 (2,361) (4,780)
Accrued expenses and other current liabilities 10,118 (15,139) 8,962
Other long-term liabilities     (25)
Deferred revenue 3,756 (3,459) (19,739)
Net cash used in operating activities (127,338) (148,343) (192,323)
Cash flows from investing activities:      
Purchases of property and equipment (119) (192) (292)
Capitalized software development costs (15,103) (15,056) (10,155)
Investment in less than majority owned joint venture (3,430) (3,920) (1,960)
Purchases of investments   (389,990) (499,223)
Proceeds from sales and maturities of investments   389,990 500,000
Net cash used in investing activities (18,652) (19,168) (11,630)
Cash flows from financing activities:      
Proceeds from exercise of common stock options   569 5,740
Proceeds from employee stock purchase plan 1,384 2,164 2,503
Payments for the purchase of treasury stock (3) (586) (360)
Proceeds from Section 16(b) disgorgement     295
Payment of contingent consideration     (11,790)
Net cash provided by (used in) financing activities 1,381 2,147 (3,612)
Effect of exchange rates changes on cash, cash equivalents, and restricted cash 887 (1,144) (305)
Net decrease in cash, cash equivalents, and restricted cash (143,722) (166,508) (207,870)
Cash, cash equivalents, and restricted cash at beginning of period 372,833 539,341 747,211
Cash, cash equivalents, and restricted cash at end of period 229,111 372,833 539,341
Cash, cash equivalents, and restricted cash at end of period:      
Cash and cash equivalents 228,316 372,038 538,546
Restricted cash 795 795 795
Total cash, cash equivalents, and restricted cash at end of period 229,111 372,833 539,341
Supplemental disclosure of cash flow information:      
Cash paid for income taxes $ 4,105 $ 5,003 1,723
Supplemental disclosure of non-cash investing and financing activities:      
Issuance of common stock in settlement of earnout     $ 17,243